Clinical trial
Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung…
NCT00029003 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00029003 |
|---|---|
| Title | Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer |
| Official title | Phase II Trial of Chronic Oral ZD1839 (Iressa®) (NSC-715055) in Both Previously-Untreated and Previously-Treated Patients With Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bronchoalveolar Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer |
| Intervention type | Drug, Other |
| Interventions | gefitinib, laboratory biomarker analysis |
| Enrollment | 90 |
| Start date | Dec 1, 2001 |
| Primary completion | Dec 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 28, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: